Rheumatology International

, Volume 32, Issue 12, pp 3841–3844 | Cite as

Predictors of early mortality in systemic sclerosis: a case–control study comparing early versus late mortality in systemic sclerosis

  • Chris T. Derk
  • Gonzalo Huaman
  • Jayne Littlejohn
  • Franklin Otieno
  • Sergio Jimenez
Original Article

Abstract

To compare the characteristics of patients with systemic sclerosis who died within 2 years of diagnosis to those who died after 2 years of diagnosis. A retrospective chart review of all medical records of deceased systemic sclerosis (SSc) patients who had been followed at our institution from 1985 to 2007 was performed. We identified 87 deceased SSc patients within this period. From the 87 deceased individuals, 20 had died within 2 years after they were diagnosed, and 67 had died after 2 years of their diagnosis. Patients who died within 2 years of diagnosis were more likely to be anticentromere antibody negative when compared to the patients who died after 2 years (17/20 vs. 48/67, P = 0.03). The time from the first appearance of non-Raynaud’s symptoms to diagnosis was significantly shorter in the group who died within 2 years than in the group who died after 2 years of diagnosis (11.8 ± 10.3 vs. 60.7 ± 64.9 months, P = 0.002). According to the Medsger severity score, there was more severe muscle (0.82 ± 1.13 vs. 1.8 ± 1.28, P = 0.0014) and heart (0.86 ± 1.37 vs. 2.1 ± 1.71, P = 0.0013) involvement at the initial evaluation in patients who died before 2 years of diagnosis when compared to the group of patients who died after 2 years of diagnosis. The time from the first symptoms to treatment initiation was significantly shorter in patients who died early (9.43 ± 6.3 vs. 38.3 ± 54.4 months, P = 0.05). The interval between treatment initiation and death was also significantly shorter (15.1 ± 9.48 vs. 60.7 ± 49.7 months, P = 0.001), reflecting greater severity of disease. Patients who died within the first 2 years of SSc diagnosis were typically anticentromere negative and had significant muscle and cardiac involvement. The time from the first appearance of non-Raynaud phenomenon symptoms to death was much shorter in the patients who died within 2 years of diagnosis, suggesting a very fulminant form of systemic sclerosis.

Keywords

Systemic sclerosis Scleroderma Mortality Death Fibrosis Poor prognosis 

Notes

Conflict of interest

The authors have no conflicts to disclose.

References

  1. 1.
    Bryan C, Howard Y, Brennan P, Black C, Silman A (1996) Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 35:1122–1126PubMedCrossRefGoogle Scholar
  2. 2.
    Bu-Shakra M, Lee P (1995) Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 22:2100–2102Google Scholar
  3. 3.
    Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48:2246–2255PubMedCrossRefGoogle Scholar
  4. 4.
    Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr (2011) Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 70(1):104–109PubMedCrossRefGoogle Scholar
  5. 5.
    Shervin A, Del Junco D, Sutter K et al (2009) Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 61:1403–1411CrossRefGoogle Scholar
  6. 6.
    Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944PubMedCrossRefGoogle Scholar
  7. 7.
    Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A et al (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118:2–10PubMedCrossRefGoogle Scholar
  8. 8.
    Simeon CP, Armadans L, Fonollosa V et al (2003) Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 42:71–75PubMedCrossRefGoogle Scholar
  9. 9.
    Ferri C, Valentini G, Cozzi F et al (2002) Demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 81:139–153PubMedCrossRefGoogle Scholar
  10. 10.
    Jacobsen S, Ullman S, Shen GQ et al (2001) Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 28:2454–2459PubMedGoogle Scholar
  11. 11.
    Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRefGoogle Scholar
  12. 12.
    Bryan C, Knight C, Black CM, Silman AJ (1999) Prediction of five-year survival following presentation with scleroderma. Arthritis Rheum 42:2660–2665PubMedCrossRefGoogle Scholar
  13. 13.
    Bulpitt KJ, Clements PJ, Lachenbruch PA et al (1993) Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma. Ann Intal Med 118:602–609Google Scholar
  14. 14.
    Altman RD, Medsger TA Jr, Block DA, Michel BA (1991) Predictors of survival in systemic sclerosis. Arthritis Rheum 34:403–413PubMedCrossRefGoogle Scholar
  15. 15.
    Medsger TA Jr (2000) Assessment of damage and activity in systemic sclerosis. Curr Opin Rheum 12:545–548CrossRefGoogle Scholar
  16. 16.
    Kuwana M, Kaburaki J, Okano Y et al (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75–83PubMedCrossRefGoogle Scholar
  17. 17.
    Mittoo S, Wigley FM, Wise RA et al (2011) Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. Open Rheumatol J 5:1–6PubMedGoogle Scholar
  18. 18.
    Bussone G, Mouthon L (2011) Interstitial lung disease in systemic sclerosis. Autoimmun Rev 10:248–255PubMedCrossRefGoogle Scholar
  19. 19.
    York RI, Farber HW (2011) Pulmonary hypertension screening and evaluation in scleroderma. Curr Opin Rheumatol 23(6):536–544PubMedCrossRefGoogle Scholar
  20. 20.
    Nikpour M, Stevens WM, Herrick AL et al (2010) Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol 24(6):857–869PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Chris T. Derk
    • 1
  • Gonzalo Huaman
    • 2
  • Jayne Littlejohn
    • 2
  • Franklin Otieno
    • 2
  • Sergio Jimenez
    • 3
  1. 1.Division of RheumatologyUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Division of RheumatologyThomas Jefferson UniversityPhiladelphiaUSA
  3. 3.Department of DermatologyThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations